No Data
No Data
Genmab's TEPKINLY Gains EU Approval for Lymphoma
ABBV.US's potential blockbuster bispecific antibody therapy has once again been approved by the European Union.
On August 20th, AbbVie (ABBV.US) and genmab (GMAB.US) jointly announced that the European Commission has approved Tepkinly (epcoritamab) for expanded indications for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) in adult patients.
Decoding 10 Analyst Evaluations For Genmab
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
Express News | Genmab Shares Are Trading Lower After JP Morgan Downgraded the Stock From Overweight to Neutral
Buy Rating Affirmed for Genmab Following Epcoritamab's European Approval and Strong Pipeline Potential